7 results about "Cancer marker" patented technology

The present application relates to the medical technical field, especially to the application of FYB1 gene as a marker in preparation of gastric cancer diagnosis or prognosis judging reagent. The present application research finds that FYB1 gene is highly expressed in gastric cancer tissue and negatively correlated with the prognosis of patients, and can be used as a gastric cancer marker for gastric cancer detection and efficacy evaluation. In addition, FYB1 is positively correlated with the expression of Treg cell marker FOXP3 and co-localized in tissues, suggesting that FYB1 may promote gastric cancer tumor immune escape; the expression of FYB1 gene can significantly inhibit the proliferation, migration and invasion ability of gastric cancer cells, and inhibit tumor growth, indicating that FYB1 gene can be used as a gastric cancer treatment target and play an important role in the treatment of gastric cancer patients.

The application provides a plasma exosome mRNA biomarker and application thereof in construction of a gastric cancer diagnosis model, and relates to the technical field of biological medicine.The application first discovers that plasma exosome mRNA MORC3 is significantly enriched in plasma of gastric cancer patients, indicating that the plasma exosome mRNA MORC3 is expected to be used as a biomarker for gastric cancer diagnosis and as a target gene for treatment of gastric cancer.We take the plasma exosome mRNA MORC3 as a target marker to construct a diagnosis model and a corresponding diagnosis system for gastric cancer.The diagnosis model provided by the application shows high sensitivity and specificity in distinguishing gastric cancer patients from healthy people, displays good diagnosis efficiency, and can effectively identify gastric cancer patients, thereby providing an effective auxiliary tool for clinical diagnosis.The application provides a new choice for a molecular marker for gastric cancer diagnosis, overcomes the low sensitivity of existing cancer markers when used for gastric cancer diagnosis, and provides a new method for early screening and diagnosis of gastric cancer.

Recently, aptamers have been considered in cancer diagnosis and treatment applications by binding to various bioreceptor molecules. Given that the p53 protein is responsible for approximately 50% of cancers, its identification is promising, but so far, no aptamer DNA sequence has been designed for the p53 protein and aptamer-based sensor. The purpose of this invention is to develop a nanoparticle-based aptamer sensor and use the p53 bioreceptor for cancer diagnosis with high sensitivity in the shortest time. In this regard, a DNA aptamer-based sensor was used on a glassy carbon electrode coated with gold nanoparticles / graphene oxide / conductive polymer . This sensor was created by the gold nanoparticles / aptamer-toluidine blue enhancer. The results obtained under optimal conditions of electrochemical investigation using amperometry indicated a detection limit of 0.29 picograms / mL in phosphate buffer and 0.341 picograms / mL in human blood plasma and a linear range of 1 to 300 picograms / mL for the sensor. This invention demonstrates the excellent and controllable performance of a modified carbon electrode to create a suitable sensor for detecting the cancer marker p53 protein.

A technique for detecting a specific protein that is suitable as a cancer marker with high sensitivity. This technique includes a method for detecting CEACAM1, which involves denaturing CEACAM1 in a CEACAM1-containing specimen to produce a denatured CEACAM1; and detecting CEACAM1 by a sandwich assay using both a capture antibody and a labeled antibody that have an ability to recognize the denatured CEACAM1.

The application provides an immunochemical luminescence kit for detecting a cancer marker HPV18 E7 protein, the kit comprising biotin-labeled antibody 1 and acridinium ester-labeled antibody 2; the antibody 1 is a rabbit-derived monoclonal antibody, comprising a heavy chain and a light chain; the antibody 1 heavy chain variable region comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO. 1-3; the antibody 1 light chain variable region comprises VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences shown in SEQ ID NO. 9-11; the antibody 2 is a rabbit-derived monoclonal antibody, comprising a heavy chain and a light chain; the antibody 2 heavy chain variable region comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO. 17-19; and the antibody 2 light chain variable region comprises VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences shown in SEQ ID NO. 25-27. The application can improve the test sensitivity, improve the detection rate of weak positive samples, realize accurate quantification of HPV18 E7 protein in cervical exfoliated cells, and the detection method of the application is simple in operation, fully automatic in the detection process, and can greatly improve the detection efficiency.

The present invention provides a method for regulating proliferation of isolated hepatocarcinoma cells. According to an embodiment of the present invention, at least one of HKDC1 expression or protein kinase activity or RBBP5 phosphorylation level is regulated in the hepatocarcinoma cells. According to the method of an embodiment of the present invention, the proliferation rate of the isolated hepatocarcinoma cells can be significantly regulated.

The application provides an immunochemiluminescence kit for detecting a cancer marker HPV16 E7 protein, the kit comprising biotin-labeled antibody 1 and acridinium ester-labeled antibody 2; the antibody 1 is a mouse monoclonal antibody, comprising a heavy chain and a light chain; the amino acid sequence of the antibody 1 heavy chain is shown in SEQ ID NO: 17, and the amino acid sequence of the antibody 1 light chain is shown in SEQ ID NO: 18; the antibody 2 is a rabbit-derived monoclonal antibody, comprising a heavy chain and a light chain; the antibody 2 heavy chain variable region comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO. 1-3; and the antibody 2 light chain variable region comprises VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences shown in SEQ ID NO. 9-11. The application can improve test sensitivity, improve the detection rate of weak positive samples, identify early cervical cancer, realize accurate quantification of HPV16 E7 protein in cervical exfoliated cells, and has the advantages of simple operation, automatic detection process and greatly improved detection efficiency.